These findings, together with our observations, suggest that targeting PARP2 with PARP inhibitors, restoring SMAD4-mediated apoptotic pathways, or counteracting PTEN loss through inhibition of the PI3K/AKT pathway may represent promising strategies to enhance treatment efficacy in CRC. The gene discussed is PARP1; the disease is colorectal carcinoma.